SHANGHAI – Hutchison China Meditech Ltd. (Chi-Med), of Shanghai, presented at the recent American Society of Clinical Oncology meeting in Chicago full phase III data for fruquintinib, an oral VEGF inhibitor, for third-line colorectal cancer (CRC).